These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37302449)

  • 21. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Matsuoka K; Watanabe M; Ohmori T; Nakajima K; Ishida T; Ishiguro Y; Kanke K; Kobayashi K; Hirai F; Watanabe K; Mizusawa H; Kishida S; Miura Y; Ohta A; Kajioka T; Hibi T;
    Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):648-657. PubMed ID: 35366419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial.
    Mules TC; Lavender B; Maclean K; Vacca F; Noble SL; Yumnam B; Te Kawa T; Cait A; Tang J; O'Sullivan D; Gasser O; Stanley J; Le Gros G; Camberis M; Inns S
    Inflamm Bowel Dis; 2024 May; 30(5):735-745. PubMed ID: 37318363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis.
    Iqbal U; Anwar H; Quadri AA
    Am J Med Sci; 2018 Oct; 356(4):350-356. PubMed ID: 30360803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
    Scaioli E; Sartini A; Bellanova M; Campieri M; Festi D; Bazzoli F; Belluzzi A
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1268-1275.e2. PubMed ID: 29391271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Danese S; Neurath MF; Kopoń A; Zakko SF; Simmons TC; Fogel R; Siegel CA; Panaccione R; Zhan X; Usiskin K; Chitkara D
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2526-2534.e9. PubMed ID: 31926340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Fluconazole Therapy in Patients With Active Ulcerative Colitis Who Have Detectable Candida in the Stool : A Double-Blind Randomized Placebo-controlled Trial.
    Jena A; Dutta U; Shah J; Sharma V; Prasad KK; Shivaprakash RM; Mandavdhare HS; Samanta J; Sharma P; Popli P; Sharma AK; Sinha SK; Chakrabarti A; Kochhar R
    J Clin Gastroenterol; 2022 Sep; 56(8):705-711. PubMed ID: 34516459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate for induction of remission in ulcerative colitis.
    Chande N; Wang Y; MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
    Yoshimura N; Watanabe M; Motoya S; Tominaga K; Matsuoka K; Iwakiri R; Watanabe K; Hibi T;
    Gastroenterology; 2015 Dec; 149(7):1775-1783.e2. PubMed ID: 26327130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial.
    Kedia S; Bhatia V; Thareja S; Garg S; Mouli VP; Bopanna S; Tiwari V; Makharia G; Ahuja V
    World J Gastrointest Pharmacol Ther; 2017 May; 8(2):147-154. PubMed ID: 28533925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.